Kyverna Therapeutics (NASDAQ:KYTX) Downgraded by Wall Street Zen to “Sell”

Kyverna Therapeutics (NASDAQ:KYTX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Other equities research analysts also recently issued reports about the stock. Morgan Stanley set a $33.00 price target on shares of Kyverna Therapeutics in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Finally, Wells Fargo & Company lifted their target price on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.67.

Kyverna Therapeutics Stock Down 7.0%

NASDAQ:KYTX opened at $7.94 on Friday. Kyverna Therapeutics has a 52 week low of $1.78 and a 52 week high of $13.67. The stock’s fifty day moving average is $8.36 and its two-hundred day moving average is $7.44. The company has a market capitalization of $347.77 million, a P/E ratio of -2.13 and a beta of 3.32.

Institutional Trading of Kyverna Therapeutics

Large investors have recently made changes to their positions in the company. Empowered Funds LLC purchased a new position in Kyverna Therapeutics in the fourth quarter worth approximately $169,000. Quadrature Capital Ltd acquired a new position in Kyverna Therapeutics during the 4th quarter worth approximately $539,000. Millennium Management LLC increased its position in shares of Kyverna Therapeutics by 7.6% in the 4th quarter. Millennium Management LLC now owns 593,369 shares of the company’s stock valued at $5,578,000 after purchasing an additional 41,734 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at $9,220,000. Finally, 683 Capital Management LLC acquired a new stake in shares of Kyverna Therapeutics in the 4th quarter valued at $1,080,000. 18.08% of the stock is currently owned by hedge funds and other institutional investors.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.